期刊文献+

新抗胆碱能药物格隆溴铵 被引量:10

Glycopyrronium bromide —— a new long-acting anti-cholinergic agent
下载PDF
导出
摘要 作为一个新长效抗胆碱能药物,格隆溴铵已被许多临床研究证实能在5min内起效且作用时间达24h,能减少慢性阻塞性肺病患者的呼吸急促、病情恶化和急救药物的使用,有效地改善肺功能和生活质量以及提高运动耐受性,同时耐受性和安全性良好,可用于治疗中、重度慢性阻塞性肺病。 As a new long-acting anti-cholinergic agent, glycopyrronium bromide has shown that it has a fast-onset of action (within 5 rain after inhalation) and 24-hour bronchodilatory effect by many clinical studies. The shortness of breath, exacerbations and the use of rescue medication can be reduced and lung function, quality of life and exercise tolerance can be effectively improved as well when glycopyrronium bromide is used in the treatment of patients with chronic obstructive pulmonary disease (COPD). Moreover, it shows a good safety profile and is generally well tolerated when used for the treatment of adult patients with moderate to severe COPD.
作者 郭海英 周新
出处 《上海医药》 CAS 2013年第15期10-12,共3页 Shanghai Medical & Pharmaceutical Journal
关键词 格隆溴铵 慢性阻塞性肺病 抗胆碱能药物 glycopyrronium bromide chronic obstructive pulmonary disease anti-cholinergic agent
  • 相关文献

参考文献7

  • 1Zhong N, Wang C, Yao W, et al. Prevalence of chronicobstructive pulmonary disease in China: a large, population- based survey [J]. Am J Respir Crit Care Med, 2007, 176(8): 753-760.
  • 2GOLD Executive Committee. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Revised 2011) [EB/OL]. [2013-01-13]. http://www.goldcopd.org/uploads/users/files/ GOLD Reoort 2011 Feb21.ndf.
  • 3European Medicines Agency. Seebri Breezhaler - Summary of Product Characteristics [EB/OL]. [2013-02-10]. http:// www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_ Product_Information/human/002430/WC500133769.pdf.
  • 4D'Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to- severe COPD: the GLOWI trial [J]. Respir Res, 2011, 12: 156.
  • 5Kerwin E, H6bert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52 weeks: the GLOW2 study [J]. Eur Respir J, 2012, 40(5): 1106-1114.
  • 6Beeh KM, Singh D, Di Scala L, et al. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial [J]. Int J COPD, 2012, 7(1): 503-513.
  • 7Gupta P, Mahony MS. Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing [J]. Drugs Aging, 2008, 25(5): 415-443.

同被引文献115

引证文献10

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部